We are excited to announce enrollment of the first patient in a Phase 2 trial of IL-18 targeted fusion protein, EVO301, in adult patients with moderate to severe atopic dermatitis. https://lnkd.in/gBvjy86R
Evommune
Biotechnology Research
Palo Alto, California 3,216 followers
Inventing ways to treat inflammatory diseases, developing therapies that address symptoms and halt progressive disease.
About us
Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.
Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease.
Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.
- Website
-
www.evommune.com
External link for Evommune
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Palo Alto, California
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Chronic Disease, Inflammatory Disease, Biotechnology, Medicines, Patient Care, and Research and Development
Locations
-
Primary
Get directions
Palo Alto, California, US
Employees at Evommune
Updates
-
Thank you to the New York Stock Exchange (NYSE) for inviting our CEO, Luis Peña, to participate in The Cure(ious) video series, where he joined fellow industry leaders in sharing their thoughts on their careers and the future of healthcare. If you’re Cure(ious) yourself, watch these videos to see which beliefs Luis holds steadfast and what inspires him and the team at Evommune. https://lnkd.in/gz96XdiA
-
Evommune reposted this
Congratulations to Dr. Eugene Bauer, our Chief Medical Officer, on receiving the Discovery Award, an honorary award by The Dermatology Foundation, for your remarkable research accomplishments impacting patients living with inflammatory diseases. It is a well-deserved and rarely given recognition. Evommune is fortunate to have such an accomplished clinician on our team, as we advance development of new treatments for patients suffering from chronic inflammatory diseases. American Academy of Dermatology Dermatology Foundation Dermatology Times
-
-
Congratulations to Dr. Eugene Bauer, our Chief Medical Officer, on receiving the Discovery Award, an honorary award by The Dermatology Foundation, for your remarkable research accomplishments impacting patients living with inflammatory diseases. It is a well-deserved and rarely given recognition. Evommune is fortunate to have such an accomplished clinician on our team, as we advance development of new treatments for patients suffering from chronic inflammatory diseases. American Academy of Dermatology Dermatology Foundation Dermatology Times
-
-
We are proud to sponsor the 2025 Dermatology Innovation Forum, hosted by @Advancing Innovation in Dermatology! Please stop by our booth to learn more about Evommune and our efforts to deliver new treatment options for patients suffering from chronic inflammatory diseases. #DIF2025 #AdvancingDerm #Dermatology
-
-
The Evommune team will attend the Leerink Partners Global Healthcare Conference in Miami and is available for one-on-one meetings on Tuesday, March 11. We hope to see you there! Kyle Carver Luis Peña Mark Jackson
-
-
The Evommune team is looking forward to participating in the Guggenheim Biotech Conference this week, which includes the panel discussion "Taming the Inflamed: Novel Approaches to Treating Inflammatory Diseases" with our CEO, Luis Pena, on Thursday, February 6, from 11-11:55 a.m. EST. We'll see you there!
-
-
We are proud to be a sponsor of the 2025 Dermatology Summit hosted by @Advancing Innovation in Dermatology! We look forward to participating in this year's conference, where Mark Jackson, our Vice President of Clinical Development, will participate in a fireside chat centered on mast cell therapies. The 2025 Dermatology Summit brings together members of the financial community and business leaders from established and emerging companies in the dermatology space. You can register for the conference on January 12th here: https://lnkd.in/gkjuR8mg #DermatologySummit #AdvancingDerm #Dermatology
-
-
Check out Mark Jackson Q&A with Dermatology Times on proof-of-concept trial results with our investigational oral MRGPRX2 antagonist, EVO756. #inflammation #urticaria #biotechnology #atopicdermatitis
-
We’re pleased to announce today’s podium clinical presentation by Romi Saini at the 7th GA²LEN Global Urticaria Forum in Berlin. Data from our first-in-human proof-of-concept trial suggests the potential of EVO756 as a first and best-in-class opportunity for patients suffering from various mast cell-mediated diseases, including urticarias. Check out today’s press release for more information: https://lnkd.in/gX6B4jqD
-